View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 7, 2022

Antisoma obtains global licence for eRapid technology

The deal will allow Antisoma to create a rapid point-of-care test platform for Covid-19 and other disease biomarkers.

iQ Group Global member Antisoma Therapeutics has secured a worldwide licence for Harvard University’s eRapid technology for creating at-home diagnostic testing.

The new diagnostic technology, developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University, was designed with exclusivity in cancer, respiratory viral illnesses and immune/allergic disease.

The affinity-based electrochemical sensing platform will be used to create rapid point-of-care diagnostic tests to detect a range of biomarkers, including prostate-specific antigen (PSA), Covid-19 antibodies and histamine.

It can be used for the simultaneous detection of a wide range of biomarkers, with high selectivity and sensitivity in complex biological fluids.

At present, the eRapid technology can be utilised for the detection of glucagon, insulin, IL6, and COVID IgM and/or IgG antibodies. This can indicate an individual’s SARS-CoV-2 virus immunity.

The iQ Group Global CEO and chairman Dr George Syrmalis said: “Our priority is to continue developing and commercialising the saliva quantitative Covid test, standardised against the World Health Organization (WHO) reference standard, which will allow patients and physicians to determine immunity based on antibody load and that will then determine if additional Covid vaccination booster shots are needed.

“This level of accuracy will rationalise repeat vaccination protocols, increase the efficiency of health care services while dramatically reducing costs to governments and the health care sector.

“The eRapid diagnostic tests have been shown to successfully detect IL6, insulin and glucagon, among other clinically relevant target molecules ranging in size from 100Da to 150,000Da. The sensors can also be reused multiple times.”

The company has been partnered with the Wyss Institute for the development of rapid point-of-care SARS-CoV-2 antibody tests since 2020.

In the same year, The iQ Group Global initially secured access to the eRapid technology for a limited-term, on a non-exclusive basis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network